Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab and Regorafenib in KRAS/NRAS Wild-type Colorectal Cancer
NCT02199223Phase 1Terminated
- Sponsor
- University of Utah
- Start
- Jun 2014
- Primary completion
- May 2016
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of panitumumab and regorafenib in colorectal cancer (CRC), sponsored by University of Utah. Primary endpoint: Number and severity of adverse events at 12 weeks. Started Jun 2014; status: terminated.
02
Drugs
panitumumabregorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02199223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02199223.